The Latest
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Eikon’s offering is the sector’s largest by total proceeds since Acelyrin secured $540 million in an IPO nearly three years ago.
Updated Feb. 4, 2026 -
Scott Olson via Getty Images
Obesity drugsLilly soars again as fast-selling weight loss drugs top Wall Street projections
Despite some angst over pricing pressure for GLP-1 drugs, Lilly’s bullish projections surpassed consensus estimates, while combined 2025 sales of Zepbound and Mounjaro eclipsed $36 billion.
-
Permission granted by Novo Nordisk
Novo shares tumble by double digits on grim sales outlook
In contrast to Lilly’s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13% decline in 2026 profits.
-
Leigh Vogel via Getty Images
Express Scripts reaches ‘landmark’ settlement with FTC in insulin suit
The agreement announced Wednesday includes sweeping changes to the Cigna PBM’s business practices, including no longer preferring expensive drugs over cheaper equivalents on standard formularies and reshoring its controversial rebate aggregator.
Updated 23 hours ago -
Win McNamee via Getty Images
Trump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions
The funding package ends a partial government shutdown and enacts several healthcare policies, including preserving telehealth flexibilities in Medicare through 2027.
-
Getty Images
Obesity drugsPfizer dips on new data for obesity drug acquired in $10B deal
A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.
-
Getty Images
News roundupFDA launches ‘PreCheck’ program; AstraZeneca, Acadia drugs set back
The agency’s program will be open to pharmaceutical facilities that align with “national priorities.” Elsewhere, a self-administered lupus drug was turned back and MeiraGTx picked up another gene therapy.
-
Getty Images
Gene editingGSK walks away from pioneering Wave RNA editing drug
Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because Wave is better suited to quickly advance a rare disease therapy.
Updated Feb. 2, 2026 -
Courtesy of Novo Nordisk
Obesity drugsNovo combination obesity shot meets goal in diabetes trial
CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to rival Lilly's Zepbound.
-
Courtesy of Sanofi
Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials
The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of Gaucher disease.
-
Alamy
Amgen gives up on its once-prized eczema drug
The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of autoimmune drugs thought to be challengers to treatments like Dupixent.
-
Alamy
China competitionAstraZeneca leans into obesity, striking wide-ranging alliance with China’s CSPC
The deal, which involves up to eight “next-generation” weight loss medications and could be worth more than $18 billion, ranks as the largest licensing pact of its kind since the start of 2025, according to BioPharma Dive data.
-
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
Roche’s deal with RNAi specialist SanegeneBio — which involves a $200 million upfront payment and $1.5 billion in future consideration — is its fourth licensing deal with a China-based drug developer since October.
Updated Feb. 3, 2026 -
Brian Tucker / BioPharma Dive/BioPharma Dive
The biopharma industry outlook on 2026: Optimism and tension
A spike in M&A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce competition from China could short-circuit the sector's resurgence.
-
Getty Images
News roundup
Moderna holds a ‘garage sale’; Roche defends obesity drug data
Moderna licensed out a rare disease drug for what an analyst called a “modest” sum. Elsewhere, Roche executives suggested better forthcoming obesity results and Summit’s PD-1/VEGF blocker got an FDA decision date.
-
Andrew Harnik/ via Getty Images
Q&APoliticization runs deeper than ever at FDA, risking long-term impacts
A massive overhaul of staffing and review processes have left the agency appearing heavily driven by the Trump administration’s political agenda, according to an economist and public policy expert.
-
Robert Way via Getty Images
China competitionAstraZeneca strengthens China ties with planned $15B investment
AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in dealmaking activity involving large pharmaceutical companies and their counterparts in China.
-
Getty Images
Regenxbio gene therapy trials suspended by FDA over safety worries
The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing and a treatment for Hunter syndrome nearing an FDA decision.
-
Courtesy of Sanofi
Vaccines
Sanofi expects vaccine sales growth to dip amid ‘challenging environment’
On a conference call, executives cited “confusion” and declining vaccination rates in the U.S. while discussing a quarterly sales decline and anticipated slower growth in 2026.
-
Getty Images
Emerging biotechTenpoint wins FDA nod for combination presbyopia eye drop
The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an advance over existing treatments from AbbVie and others.
-
Permission granted by Roche
Obesity drugsRoche, trailing in obesity, showcases new data for GLP-1 shot
A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts said.
-
Getty Images
Gene editingLilly bets on Seamless, delving further into genetic medicine for hearing loss
The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge treatments the company is developing for hearing disorders.
-
anouchka via Getty Images
Deep Dive5 questions facing biopharma in 2026
The biopharmaceutical sector finally regained its footing in 2025. Here are five issues that could determine whether the renewed optimism will carry over into the new year.
-
Getty Images
Trump administrationDrugs for cancer, arthritis and HIV on Medicare’s list for 2028 price cuts
Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — draw very limited revenue from Medicare, an analyst pointed out.
-
Kevin Frayer via Getty Images
China competitionChina’s edge in early-stage drugmaking ‘likely to persist,’ Pitchbook says
The ongoing surge in licensing deals for early drug prospects should continue this year and involve more cell and gene therapies, which have had trouble securing funding in the U.S., the firm said in a new report.
